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ABSTRACT: A bioinspired cocoon-like anticancer drug
delivery system consisting of a deoxyribonuclease
(DNase)-degradable DNA nanoclew (NCl) embedded
with an acid-responsive DNase I nanocapsule (NCa) was
developed for targeted cancer treatment. The NCl was
assembled from a long-chain single-stranded DNA
synthesized by rolling-circle amplification (RCA). Multiple
GC-pair sequences were integrated into the NCl for
enhanced loading capacity of the anticancer drug
doxorubicin (DOX). Meanwhile, negatively charged
DNase I was encapsulated in a positively charged acid-
degradable polymeric nanogel to facilitate decoration of
DNase I into the NCl by electrostatic interactions. In an
acidic environment, the activity of DNase I was activated
through the acid-triggered shedding of the polymeric shell
of the NCa, resulting in the cocoon-like self-degradation of
the NCl and promoting the release of DOX for enhanced
therapeutic efficacy.
Self-assembled DNA nanostructures have been developedwith precisely controlled size and architecture.1 Because of
DNA’s intrinsic biocompatibility and degradability, DNA
nanostructures hold tremendous promise for drug delivery.
Numerous cargoes, including small-molecule drugs,2 small
interfering RNA (siRNA),1a,3 the immunostimulatory oligonu-
cleotide CpG,4 photosensitizers,5 and proteins,1b have been
successfully delivered intracellularly by DNA nanocarriers.
Moreover, DNA-based carriers can be readily functionalized
either by hybridizing a targeting moiety onto the nano-
structure1a or programming a targeting aptamer into the DNA
chain1b,c for targeted drug delivery. Despite these advances,
strategies utilizing DNA scaffolds for on-demand drug delivery
in a stimuli-responsive fashion,6 instead of passive release,7 still
remain elusive. We have recently reported an adenosine
triphosphate (ATP)-responsive formulation incorporating
short DNA strands (with ATP’s aptamer) loaded with
doxorubicin (DOX), an anticancer drug.8 The enhanced drug
release inside cancer cells triggered by a high ATP level was
validated. However, this design is limited by a complicated
formulation process and relatively low drug loading capacity.
We herein describe a bioinspired drug delivery carrier in
which a cocoon-like DNA nanocomposite is integrated with
“caged worm” deoxyribonuclease (DNase) to achieve self-
degradation for promoting drug release inside cells (Figure 1).
The DNA structure is based on a “nanoclew” (denoted as NCl)
that is “woven” by rolling-circle amplification (RCA) [Scheme
S1 in the Supporting Information (SI)], the product of which is
often applied in biodetection.9 Multiple GC-pair sequences are
integrated into the NCl to enhance the loading capacity of
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Figure 1. (a) Main components of the cocoon-like self-degradable
DNA nanoclew, consisting of DOX/FA-NCl/NCa, and acid-triggered
DOX release. (b) Schematic illustration of efficient delivery of DOX
by DOX/FA-NCl/NCa to nuclei for cancer therapy: (I) internal-
ization in endosomes; (II) pH-triggered degradation of the NCl for
DOX release; (III) accumulation of DOX in cell nuclei.
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DOX.8 To facilitate self-assembly, a palindromic sequence is
incorporated into the template. To enable degradation of NCl,
DNase I is encapsulated into a single-protein-based nano-
capsule (denoted as NCa) with a positively charged thin
polymeric shell that is cross-linked by acid-degradable cross-
linkers using interfacial polymerization (Figure 1a).10 Fur-
thermore, to achieve tumor-targeting delivery of DOX, folic
acid (FA) is conjugated to an NCl complementary DNA
(cDNA) oligomer followed by hybridization to the DNA NCl.
The positively charged NCa can be embedded into the NCl via
electrostatic interactions to form the DOX-loaded self-
degradable DNA scaffold (designated as DOX/FA-NCl/
NCa). The polymeric capsule cages the activity of DNase I at
physiological pH, causing DOX to be retained in the NCl.
When DOX/FA-NCl/NCa is internalized by cancer cells and
enters the acidic endolysosome, the polymeric shell of NCa
degrades and is shed from DNase I. This results in the
immediate rejuvenation of DNase I, which rapidly degrades
NCl, thereby releasing the encapsulated DOX for enhanced
anticancer efficacy (Figure 1b). This formulation represents a
novel stimuli-responsive drug delivery system, the trigger of
which is preloaded with the delivery vehicle and can be
activated by the cellular environment.
To validate our assumption, we first synthesized the DNA
NCl by RCA (the sequence is shown in Table S1 in the SI).
Cyclization of the single-stranded DNA (ssDNA) template was
confirmed by its resistance to Exonuclease I, and RCA products
with various molecular weights were amplified from the circular
ssDNA template (Figure S1 in the SI). NCl exhibited high
stability after incubation with culture medium containing fetal
bovine serum (FBS) (10% v/v) for up to 48 h (Figure S1c).
The synthesized ssDNA self-assembled into the three-dimen-
sional clew-like structure with an average particle size of 150
nm (Figure 2a). Intercalation of DOX into NCl was monitored
via the fluorescence intensity of the DOX solution, which
significantly declined when NCl was added as a result of self-
quenching8 of DOX upon interacting with the NCl (Figure S2).
The DOX loading was also assessed (Figure S3). It was found
that at a mass ratio of 2.3, NCl showed a maximum DOX-
loading capacity of 66.7%, and 86.5% of the added DOX was
entrapped in the obtained NCl.
Both native DNase I and the obtained NCl had negatively
charged surfaces (Table S2). To integrate them together,
DNase I was encapsulated in a positively charged polymeric
single-protein nanogel by means of in situ free-radical
polymerization,10b which encapsulated DNase I into a capsule
with the ζ potential converted from −9 to +3 mV.
Monodispersed NCa was obtained with an average particle
size of 8.0 nm, which is larger than the size of the native DNase
I (4.2 nm) (Figure 2b). Encapsulating DNase I in the capsule
had no impact on its secondary structure (Figure 2c), and acid-
responsive degradation11 of NCa was observed (Figure S4).
Glycerol dimethacrylate (GDA), the pH-responsive cross-linker
in NCa, is stable at physiological pH but degradable at a lower
pH,10a NCa degradation was observed after incubation at pH
5.4 for 2 h. The particle size of NCa was remarkably decreased
at pH 5.4 compared with that at pH 7.4.
To further substantiate the pH-responsive DNA-degrading
capability of NCa, a nondegradable DNase I capsule (cNCa)
prepared with a nondegradable cross-linker, methylenebis-
(acrylamide), in place of GDA was used as a control. The pH
responsiveness of NCa was further confirmed by testing the
enzymatic activity of DNase I (Figure 2d). Because of the
nondegradability of cNCa, the polymeric shell of cNCa
impeded the DNase I activity at both pH 7.4 and 5.4.
However, NCa showed significantly higher DNase I activity at
pH 5.4 than that at pH 7.4.
Next, we mixed negatively charged NCl with positively
charged NCa to form homogeneous NCl/NCa complexes
(PDI = 0.24 ± 0.02). The NCl/NCa assembly was observed by
the colocalization of the fluorescence signals of DOX (red) in
DOX/NCl and Alexa Fluor 488 (AF488) (green) in AF488-
modified NCa (Figure S5). The NCl/NCa assembly increased
the average hydrodynamic size of NCl from 150 to 180 nm, and
the NCl ζ potential was converted from negative to positive
(Figure 3a and Table S2). Furthermore, the TEM image clearly
showed that gold nanoparticle-labeled NCa10a,12 (Au-NCa)
(Table S2) was well-decorated onto the NCl surface (Figure
3a).
The release profiles of DOX from DOX/NCl/NCa at
different pH values were determined8a (Figure 3b), and pH
reduction resulted in promoted release of DOX. At pH 5.4, the
cumulative release of DOX within 260 min was 3.7-fold that at
pH 7.4. In contrast, there was no apparent difference in the
release of DOX from DOX/NCl/cNCa at pH 5.4 and 7.4.
Similarly, The NCl/NCa complexes remained stable at pH 7.4
for 2 h, while a high degradation efficiency of NCl/NCa
complexes was observed at pH 5.4 (Figure 3c).
To enhance the tumor-targeting efficacy of DOX/NCl/NCa,
a ligand containing FA (cDNA-PEG-FA) was hybridized into
the NCl, and the hybridization of cDNA-PEG-FA to the NCl
resulted in no significant change in the NCl particle size and ζ
potential (Table S2). The endocytosis pathway of DOX/FA-
NCl/NCa was determined by incubating human breast cancer
(MCF-7) cells overexpressing FR13 with different inhibitors for
specific pathways (Figure 4a). Compared with other inhibitors,
both chlorpromazine (CPZ) and amiloride (AMI) displayed
pronounced effects in inhibiting the internalization of DOX/
FA-NCl/NCa, suggesting that DOX/FA-NCl/NCa was in-
ternalized by the cells and localized in the acidic endosomes.
Figure 2. (a) Hydrodynamic size of NCl as determined by dynamic
light scattering (DLS). Inset: atomic force microscopy (AFM) image
of NCl. The scale bar is 500 nm. (b) Hydrodynamic size of NCa.
Inset: transmission electron microscopy (TEM) image of NCa. The
scale bar is 10 nm. (c) Circular dichroism (CD) spectra of native
DNase I and NCa. (d) DNA-degrading activities of NCa and cNCa at
pH 7.4 and 5.4. Bars represent mean ± standard deviation (n = 3).
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The intracellular distribution of DOX/FA-NCl/NCa was
then detected (Figures 4b and S6). The internalization and
nucleus targeting of DOX/FA-NCl/NCa in MCF-7 cells was
extremely fast even within the first 10−30 min, during which
period obvious endolysosomal entrapment and nucleus
targeting of DOX could be observed. Colocalization of
DOX/FA-NCl with NCa in MCF-7 cells was also observed
(Figure S7). In the first 10 min, DOX/FA-NCl/AF488-NCa
was internalized together. The fluorescence signals of DOX and
AF488 showed a high colocalization. After 0.5 h, a large amount
of DOX was released from the DOX/FA-NCl/AF488-NCa into
the cytosol and specifically accumulated in the nucleus. Such
rapid cytosolic distribution and nucleus-targeting effects of
DOX delivered by DOX/FA-NCl/NCa were attributed to the
efficient degradation of DOX/FA-NCl by NCa to promote the
release of DOX.
The in vitro cytotoxicities of DOX/NCl, DOX/NCl/NCa,
and DOX/FA-NCl/NCa against MCF-7 cells were estimated
(Figure 4c). DOX/NCl/NCa showed a remarkably higher
cytotoxicity toward MCF-7 cells than DOX/NCl. The half-
maximal inhibitory concentration (IC50) of DOX/NCl/NCa
was calculated to be 1.2 μM, which is noticeably lower than the
value of 2.3 μM for DOX/NCl. This verified that the NCa-
mediated DOX release increased the toxicity of DOX delivered
by NCl. This was further validated by the significantly higher
cytotoxicity of MCF-7 treated with DOX/NCl/NCa than that
associated with DOX/NCl/cNCa (Figure S8). Additionally, the
conjugation of FA onto the NCl surface enhanced the
therapeutic efficacy of DOX (Figure 4c). DOX/FA-NCl/NCa
had the lowest IC50 (0.9 μM) compared with both DOX/NCl/
NCa and DOX/NCl. The blank FA-NCl without DOX showed
negligible toxicity at all tested concentrations (Figure 4d). It is
noteworthy that although DNase I, the component of the
carrier in this research, has been used as an anticancer agent in
some other studies,14 the cytotoxicity of NCa toward MCF-7 at
the selected concentration in this study was compromised
compared with that of released DOX (Figure 4d).
In summary, we have developed a bioinspired self-degradable
drug delivery system consisting of a woven DNA “nanoclew” as
a “cocoon matrix” and a “caged” DNase I nanogel as
“hibernating worms”. The “worms” can be readily activated to
degrade their cocoon to release encapsulated drugs in the
endolysosomal compartments. We will further the evaluate in
vivo anticancer efficacy and biocompatibility of this delivery
system. Our unique strategy provides insights for the design of
new prodrugs and can be further extended to engineer other
programmed drug delivery systems.
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Figure 3. (a) Hydrodynamic size of NCl/NCa complexes. Inset: TEM
image of an NCl/Au-NCa complex. The scale bar is 100 nm. The
arrows indicate Au-NCa adsorbed on the NCl surface. (b) DOX
release from DOX/NCl/NCa and DOX/NCl/cNCa at pH 7.4 and
5.4. Bars represent mean ± SD (n = 3). (c) AFM images of NCl/NCa
complexes after incubation at pH 7.4 and 5.4 for 2 h. The scale bar is
500 nm.
Figure 4. (a) Relative uptake efficiency of DOX/FA-NCl/NCa by
MCF-7 cells. **, P < 0.01 compared with the control. Bars represent
mean ± SD (n = 3). (b) Confocal laser scanning microscopy images of
MCF-7 cells after incubation with DOX/FA-NCl/NCa for different
times. Late endosome and lysosomes were stained with LysoTracker
green. Red, DOX; green, endolysosome; blue, Hoechst 33342; yellow,
colocalization of red and green pixels; magenta, colocalization of red
and blue pixels. The scale bar is 10 μm. (c) In vitro cytotoxicities of
DOX/NCl, DOX/NCl/NCa, and DOX/FA-NCl/NCa against MCF-7
cells for 24 h. *, P < 0.05. Bars represent mean ± SD (n = 6). (d) In
vitro cytotoxicities of the blank FA-NCl, NCa, and FA-NCl/NCa
against MCF-7 cells for 24 h. Bars represent mean ± SD (n = 6).
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